Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7428171 | 0.90 | KMT2A (0.39) | KMT2ATTRGPR35KDM4EMEN1 | |
| SCHEMBL7432592 | 0.90 | KMT2A (0.39) | KMT2ATTRGPR35KDM4EMEN1 | |
| SCHEMBL19869338 | 0.82 | ALDH1A1 (0.39) | KMT2AALDH1A1MAPTALOX15RECQL | |
| SCHEMBL7436432 | 0.80 | TTR (0.33) | KMT2ATTRGPR35KDM4EMEN1 | |
| SCHEMBL7436428 | 0.80 | TTR (0.33) | KMT2ATTRGPR35KDM4EMEN1 | |
| SCHEMBL4686035 | 0.78 | GPR35 (0.41) | KMT2AGPR35ALDH1A1MAPTHPGD | |
| SCHEMBL31607330 | 0.75 | KMT2A (0.41) | KMT2AMEN1POLBGRIN2DGRIN3B | |
| SCHEMBL1608810 | 0.74 | KDM4E (0.44) | KMT2ATTRGPR35KDM4EMEN1 | |
| SCHEMBL7514906 | 0.74 | GRIN2D (0.33) | KMT2ATTRGPR35KDM4EMEN1 | |
| SCHEMBL7514913 | 0.74 | GRIN2D (0.33) | KMT2ATTRGPR35KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1454203-A | Substituted nitrated catechols, their use in the treatment of certain central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & CA SA (PT) | 2003-11-05 | — | — | CN | claimed |
| US-20020037931-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & C.A., S.A. (PT) | 2002-03-28 | — | — | US | claimed |
| EP-1167341-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | Portela & Ca., S.A. (PT) | 2002-01-02 | — | — | EP | claimed |
| WO-2001098250-A1 | SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PORTELA & CA SA (PT) | 2001-12-27 | — | — | WO | claimed |
| US-20020037931-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & C.A., S.A. (PT) | 2002-03-28 | — | — | US | disclosed |
| EP-1167341-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | Portela & Ca., S.A. (PT) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001098250-A1 | SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PORTELA & CA SA (PT) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037931-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | SLC6A2, COMT, SLC6A3 | KMT2A 2898/4885TTR 791/4885GPR35 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.